At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AGIO Agios Pharmaceuticals
Closed 01-21 16:00:00 EST
27.17
+0.49
+1.84%
盘后27.17
+0.000.00%
19:00 EST
High27.32Low26.42Vol1.13M
Open26.73D1 Closing26.68Amplitude3.37%
Mkt Cap1.58BTradable Cap1.40BTotal Shares58.31M
T/O30.46MT/O Rate2.21%Tradable Shares51.35M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Agios Pharma (AGIO) Gets a Buy from TD Cowen
TIPRANKS  ·  01-14
Agios Pharma (AGIO) Gets a Buy from TD Cowen
Agios Pharmaceuticals to Present Strategic Update at J.P. Morgan Healthcare Conference
Reuters  ·  01-12
Agios Pharmaceuticals to Present Strategic Update at J.P. Morgan Healthcare Conference
Agios Pharmaceuticals Announces 2026 Strategic Priorities Including AQVESME™ U.S. Thalassemia Launch, Planned Regulatory Submission for Sickle Cell Disease, and Advancement of Rare Disease Pipeline Toward Projected $1 Billion Peak Sales
Reuters  ·  01-12
Agios Pharmaceuticals Announces 2026 Strategic Priorities Including AQVESME™ U.S. Thalassemia Launch, Planned Regulatory Submission for Sickle Cell Disease, and Advancement of Rare Disease Pipeline Toward Projected $1 Billion Peak Sales
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
THOMSON REUTERS  ·  01-12
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
Agios Pharmaceuticals Inc - Pre-Snda Meeting for Mitapivat in Sickle Cell Disease Anticipated in Q1 2026
THOMSON REUTERS  ·  01-12
Agios Pharmaceuticals Inc - Pre-Snda Meeting for Mitapivat in Sickle Cell Disease Anticipated in Q1 2026
Agios Pharmaceuticals: Expects to Initiate Phase 1B Proof-of-Mechanism Trial of Ag-181 With Pku in H1 2026, Confirm Proof of Mechanism in H2 2026
THOMSON REUTERS  ·  01-12
Agios Pharmaceuticals: Expects to Initiate Phase 1B Proof-of-Mechanism Trial of Ag-181 With Pku in H1 2026, Confirm Proof of Mechanism in H2 2026
Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan
Dow Jones  ·  01-07
Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan
BofA Adjusts Price Target on Agios Pharmaceuticals to $35 From $34, Maintains Buy Rating
MT Newswires Live  ·  01-06
BofA Adjusts Price Target on Agios Pharmaceuticals to $35 From $34, Maintains Buy Rating
U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure
Reuters  ·  01-06
U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure
Agios Pharmaceuticals CEO Brian Goff Reports Disposal of Common Shares
Reuters  ·  01-03
Agios Pharmaceuticals CEO Brian Goff Reports Disposal of Common Shares
Agios Pharmaceuticals Inc : Leerink Partners Raises Target Price to $40 From $34
THOMSON REUTERS  ·  2025-12-26
Agios Pharmaceuticals Inc : Leerink Partners Raises Target Price to $40 From $34
Goldman Sachs Raises Agios (AGIO.US) Price Target to $28, Bullish on Thalassemia Drug Aqvesme's Launch Prospects
Stock News  ·  2025-12-26
Goldman Sachs Raises Agios (AGIO.US) Price Target to $28, Bullish on Thalassemia Drug Aqvesme's Launch Prospects
Agios Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  2025-12-26
Agios Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal
MT Newswires Live  ·  2025-12-25
Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal
Agios Pharmaceuticals Is Maintained at Buy by B of A Securities
Dow Jones  ·  2025-12-24
Agios Pharmaceuticals Is Maintained at Buy by B of A Securities
Agios Pharmaceuticals Exec Says Aqvesme Will Be Introduced at Approximately $425,000 per Patient per Year - Conf Call
THOMSON REUTERS  ·  2025-12-24
Agios Pharmaceuticals Exec Says Aqvesme Will Be Introduced at Approximately $425,000 per Patient per Year - Conf Call
BUZZ-Agios Pharma rises after US FDA expands use of co's drug for blood disorder
Reuters  ·  2025-12-24
BUZZ-Agios Pharma rises after US FDA expands use of co's drug for blood disorder
Agios Pharmaceuticals Shares up 9.8% Premarket After US FDA Approves Co’s Drug for Treatment of Anemia in Adults With Blood Disorder
THOMSON REUTERS  ·  2025-12-24
Agios Pharmaceuticals Shares up 9.8% Premarket After US FDA Approves Co’s Drug for Treatment of Anemia in Adults With Blood Disorder
FDA Approves Agios’ AQVESME for Anemia in Alpha- and Beta-Thalassemia
Reuters  ·  2025-12-24
FDA Approves Agios’ AQVESME for Anemia in Alpha- and Beta-Thalassemia
U.S. FDA Approves Agios’ Aqvesme™ (Mitapivat) for the Treatment of Anemia in Adults With Alpha- or Beta-Thalassemia
THOMSON REUTERS  ·  2025-12-24
U.S. FDA Approves Agios’ Aqvesme™ (Mitapivat) for the Treatment of Anemia in Adults With Alpha- or Beta-Thalassemia

Introduction

Company Name.
Agios Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Issue price:
--